FTB-918 / Fortitude Biomedicines - LARVOL DELTA

FTB-918: A Dual Targeting Antibody With TRBV9+ T Cell Depletion and IL-17A Neutralization for the Treatment of Axial Spondyloarthritis (ACR Convergence 2026) - "Palivizumab was used as an isotype control. We have developed a high-affinity antibody, FTB-918, capable of depleting TRBV9+ T cells and neutralizing IL17A. FTB-918 has robust functionality addressing two distinct mechanisms of axSpA immunopathogenesis and disease progression. The pre-clinical data illustrate the potential for FTB-918 to offer differentiated results from existing axSpA therapeutics, addressing the ongoing unmet need in this indication."

Ankylosing Spondylitis • Axial Spondyloarthritis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis • CD8 • CXCL1 • IL17A